You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Dow
Johnson and Johnson
Moodys

Last Updated: September 27, 2023

Abbott Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ABBOTT, and what generic and branded alternatives to ABBOTT drugs are available?

ABBOTT has one hundred and eleven approved drugs.



Summary for Abbott
US Patents:0
Tradenames:89
Ingredients:62
NDAs:111

Drugs and US Patents for Abbott

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride TABLET;ORAL 084160-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Abbott CALCIUM GLUCEPTATE calcium gluceptate INJECTABLE;INJECTION 080001-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial
Abbott EUTONYL pargyline hydrochloride TABLET;ORAL 013448-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Abbott GENTAMICIN SULFATE gentamicin sulfate INJECTABLE;INJECTION 062413-001 Aug 11, 1983 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Abbott A-HYDROCORT hydrocortisone sodium succinate INJECTABLE;INJECTION 089579-001 Apr 11, 1989 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Abbott A-METHAPRED methylprednisolone sodium succinate INJECTABLE;INJECTION 089574-001 Feb 22, 1991 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbott

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-004 Aug 7, 1987 5,294,615 ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-004 Aug 7, 1987 5,212,176 ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987 4,251,532 ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987 5,212,176 ⤷  Try a Trial
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 5,648,497*PED ⤷  Try a Trial
Abbott MERIDIA sibutramine hydrochloride CAPSULE;ORAL 020632-001 Nov 22, 1997 4,746,680*PED ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ABBOTT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Capsules 10 mg and 15 mg ➤ Subscribe 2009-08-14
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Moodys
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.